Applied DNA Sciences Management

Management Kriterienprüfungen 4/4

Applied DNA Sciences CEO ist James Hayward , ernannt in Mar 2006, hat eine Amtszeit von 18.67 Jahren. Die jährliche Gesamtvergütung beträgt $468.00K , bestehend aus 96.2% Gehalt und 3.8% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.013% der Aktien des Unternehmens, im Wert von $1.04K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 9.8 Jahre bzw. 8.8 Jahre.

Wichtige Informationen

James Hayward

Geschäftsführender

US$468.0k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	96.2%
Amtszeit als Geschäftsführer	18.7yrs
Eigentum des Geschäftsführers	0.01%
Durchschnittliche Amtszeit des Managements	9.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	8.8yrs

Jüngste Management Updates

Recent updates

The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%

Dec 20

Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Aug 17

Applied DNA Sciences gains as it secures ~$3.6M proceeds from warrant exercise

Aug 09

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von James Hayward im Vergleich zu den Einnahmen von Applied DNA Sciences verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$13m
Dec 31 2023	n/a	n/a	-US$7m
Sep 30 2023	US$468k	US$450k	-US$10m
Jun 30 2023	n/a	n/a	-US$7m
Mar 31 2023	n/a	n/a	-US$5m
Dec 31 2022	n/a	n/a	-US$7m
Sep 30 2022	US$2m	US$450k	-US$8m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	n/a	n/a	-US$14m
Sep 30 2021	US$1m	US$400k	-US$14m
Jun 30 2021	n/a	n/a	-US$14m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	n/a	n/a	-US$15m
Sep 30 2020	US$451k	US$133k	-US$13m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$9m
Dec 31 2019	n/a	n/a	-US$8m
Sep 30 2019	US$375k	US$233k	-US$9m
Jun 30 2019	n/a	n/a	-US$11m
Mar 31 2019	n/a	n/a	-US$12m
Dec 31 2018	n/a	n/a	-US$12m
Sep 30 2018	US$481k	US$250k	-US$12m

Vergütung im Vergleich zum Markt: JamesDie Gesamtvergütung ($USD468.00K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD647.72K).

Entschädigung vs. Einkommen: JamesDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

James Hayward (70 yo)

18.7yrs

Amtszeit

US$468,000

Vergütung

Dr. James A. Hayward, Ph D., Sc D., has been Chief Executive Officer and Chairman of Applied DNA Sciences, Inc. (Formerly Known as Prohealth Medical Tech, Inc) since March 17, 2006 and June 12, 2007, respe...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
James Hayward	Chairman	18.7yrs	US$468.00k	0.013% $ 1.0k
Beth Jantzen	Chief Financial Officer	9.8yrs	US$501.00k	0.0041% $ 317.7
Judith Murrah	COO, Chief Information Officer & Secretary	11.4yrs	US$542.75k	0.0046% $ 362.3
Clay Shorrock	Chief Legal Officer & Executive Director of Business Development	3.6yrs	US$501.00k	0.0055% $ 433.5
Sanjay Hurry	Executive Director of Investor Relations & Corporate Communications	4.3yrs	keine Daten	keine Daten

9.8yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrenes Management: APDNDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (9.8 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
James Hayward	Chairman	19.2yrs	US$468.00k	0.013% $ 1.0k
Robert Catell	Chairman of Strategic Advisory Board & Independent Director	8.8yrs	US$152.50k	0.00019% $ 14.9
Yacov Shamash	Independent Director	18.7yrs	US$162.50k	0.00016% $ 12.5
Raymond Kelly	Member of Strategic Advisory Board	7.8yrs	keine Daten	keine Daten
Joseph Ceccoli	Independent Director	9.9yrs	US$155.00k	0.000060% $ 4.7
Sanford Simon	Independent Director	18.7yrs	US$151.25k	0.000010% $ 0.8
Mehmood Khan	Member of Strategic Advisory Board	8.1yrs	keine Daten	keine Daten
Gunther Faber	Member of Strategic Advisory Board	8.8yrs	keine Daten	keine Daten
Elizabeth M. Shaheen	Independent Director	7.4yrs	US$153.75k	0.000080% $ 6.3
Stephen Birkhold	Member of Strategic Advisory Board	5.8yrs	keine Daten	keine Daten

8.8yrs

Durchschnittliche Betriebszugehörigkeit

73.5yo

Durchschnittliches Alter

Erfahrener Vorstand: APDNDie Vorstandsmitglieder gelten als erfahren (8.8 Jahre durchschnittliche Amtszeit).

Applied DNA Sciences Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Applied DNA Sciences, Inc., Annual General Meeting, Sep 30, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Apr 15, 2024

Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs

Applied DNA Sciences, Inc., Annual General Meeting, Sep 19, 2023

Insufficient new directors

Recent updates

Applied DNA Sciences, Inc. Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Applied DNA Sciences, Inc. announced that it has received funding

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.499893 million.

New major risk - Market cap size

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc.'s Applied DNA Clinical Labs, LLC Launches Mpox Clade I and Clade II Testing Service

Applied DNA Sciences, Inc. to Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I

Consensus revenue estimates fall by 20%

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Applied DNA Sciences, Inc. to Report Q3, 2024 Results on Aug 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Sep 30, 2024

Applied DNA Sciences Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Consensus EPS estimates upgraded to US$5.32 loss

Applied DNA Sciences, Inc. Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health

Applied DNA Sciences, Inc. has completed a Composite Units Offering in the amount of $12 million.

New major risk - Share price stability

New major risk - Financial position

New major risk - Shareholder dilution

Consensus estimates of losses per share improve by 24%

Applied DNA Sciences, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering.

Applied DNA Sciences, Inc. to Showcase Linea DNA and Linea IVT Platforms At 24Th Annual World Vaccine Congress

Consensus EPS estimates upgraded to US$0.65 loss, revenue downgraded

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Applied DNA Sciences, Inc. to Report Q1, 2024 Results on Feb 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Apr 15, 2024

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.436992 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.437233 million.

The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%

Consensus revenue estimates fall by 49%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Applied DNA Sciences Receives Non-Compliance Notice From Nasdaq

Applied DNA Sciences, Inc. to Report Q4, 2023 Results on Dec 07, 2023

Applied DNA Sciences, Inc. Extends Application of Linea(Tm) Ivt Platform to Sna (Self-Amplifying Mrna)

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs

Applied DNA Sciences, Inc. Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit

Applied DNA Sciences, Inc. Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Applied DNA Sciences, Inc. to Report Q3, 2023 Results on Aug 10, 2023

Applied DNA Sciences, Inc., Annual General Meeting, Sep 19, 2023

New minor risk - Share price stability

Applied DNA Sciences, Inc. (NasdaqCM:APDN) acquired Spindle Biotech Inc. for $2.8 million.

Consensus revenue estimates decrease by 13%, EPS upgraded

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Applied DNA Sciences, Inc. to Report Q2, 2023 Results on May 11, 2023

Consensus revenue estimates increase by 12%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Applied DNA Sciences, Inc. to Report Q1, 2023 Results on Feb 09, 2023

Applied DNA Sciences, Inc. Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA as New Class of DNA-Based Vaccines

Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Invest In Growth?

Consensus revenue estimates fall by 20%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Price target decreased to US$7.00

Applied DNA Sciences, Inc. to Report Q4, 2022 Results on Dec 05, 2022

Applied DNA climbs 51% after winning large purchase order

Applied DNA Sciences, Inc.'s Subsidiary, Applied DNA Clinical Labs, LLC, Launches Monkeypox Testing Service

Applied DNA stock rises 12% on launching monkeypox testing service in New York

Applied DNA Submits PCR-Based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health

Applied DNA adds 17% as company seeks approval for monkeypox test in New York

Consensus estimates of losses per share improve by 19%

Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Applied DNA Sciences gains as it secures ~$3.6M proceeds from warrant exercise